UPDATE -- CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community
March 23, 2022 06:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of...
CareDx Brings Together Leading Transplant Experts to Share Latest Advancements in the Field of Xenotransplantation
March 16, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community
March 14, 2022 20:06 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of...
CareDx Announces Cibiltech Initiates CIBIL Study Using iBox Artificial Intelligence to Monitor Kidney Transplant Patients
March 03, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
CareDx Partners with the National Kidney Foundation to Advocate for Kidney Transplant Patients
March 02, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
CareDx Reports Fourth Quarter and Full Year 2021 Results
February 24, 2022 16:01 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
CareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring World’s First Successful Living Xenotransplantation
February 22, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
CareDx to Report Fourth Quarter and Full Year 2021 Financial Results
February 17, 2022 16:01 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
On National Donor Day, CareDx Applauds Patient Advocacy Efforts Aimed at Increasing Donations for the Thousands of Patients Waiting for a Transplant
February 14, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
CareDx Taps into Its Patient Network to Deliver Insights on Transplant Needs
February 08, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...